Skip to main content
Clinical Trials/ACTRN12616001517460
ACTRN12616001517460
Terminated
Phase 2

Early PARacetamol (EPAR) to promote early closure of the ductus arteriosus in preterm infants

Timothy Schindler0 sites58 target enrollmentNovember 3, 2016

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Patent ductus arteriosus
Sponsor
Timothy Schindler
Enrollment
58
Status
Terminated
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 3, 2016
End Date
July 3, 2019
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Timothy Schindler

Eligibility Criteria

Inclusion Criteria

  • Preterm infants \<6 hours old
  • Born at \<29 weeks gestation
  • Informed parental consent
  • Ductus arteriosus characteristics
  • \- Patent \>1 mm
  • \- \<30% right to left shunt

Exclusion Criteria

  • Known congenital anomalies
  • Haemodynamic instability (\>1 ionotropic agent)
  • Abnormal baseline liver function
  • \- Transaminases \>50% above upper reference range
  • \- Bilirubin above local guideline for exchange transfusion
  • Ductus arteriosus characteristics
  • \- \>30% right to left shunt

Outcomes

Primary Outcomes

Not specified

Similar Trials